ProKidney Jefferies Global Healthcare Conference
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
All right. I'm Andrew Tsai, Senior Biotech Analyst at Jefferies. Thanks for joining me today, and it's my pleasure to have the ProKidney team with me. To my direct right, Bruce Culleton, CEO. To his right is James Coulston, CFO. And to James' right is Anthony Conway, VP, or head of IR. Welcome, all of you. Head of R&D?
R&D, yeah. Okay, yes. Good.
And so maybe give us an introduction about ProKidney for those who are less familiar with the story. What you're working on, what you're trying to achieve, what milestones we can expect over the next 6-12 months.
Yeah. Sounds good, Andrew, and thanks for inviting us to the meeting. ProKidney is a company that's based in the U.S. We've got the majority of our employees in North Carolina. We have 250 employees. Everyone is aligned, I think, to a single purpose, and that single purpose is to help patients who've got diabetes and advanced chronic kidney disease to delay the onset of dialysis or the need for a transplant. We have a product, a single product. It's an autologous cell therapy. It's called rilparencel. And we are fortunate enough to be well into our phase III clinical study. On the background of good phase II data, we finished enrollment, we finished recruitment in August. We anticipate finishing enrollment in Q1, and we expect accelerated approval readout on a surrogate endpoint in Q2 of 2027.
Perfect. So maybe to level set the market opportunity, remind us the drugs approved for non-dialysis type 2 diabetes patients with non-dialysis CKD stage 3B, four, or stage 3B4. How big is the population? What drugs are currently used at the moment?
The population, just in the U.S. alone, there are about 1 million patients who have advanced chronic kidney disease. That is late stage 3B or stage 4 chronic kidney disease. And those 1 million patients today have seen significant advances in the treatment of diabetic kidney disease over the last five years. So right now, if you are a treating physician, you have four pillars of therapeutic options that you could choose from. The older drugs are renin-angiotensin system inhibitors, ACE inhibitors, and ARBs, for example. SGLT2 inhibitors are now approved. We have non-steroidal MRAs and GLP-1s. So definitely a forward advance in how we treat patients with chronic kidney disease and diabetes. But we also understand, and this is consistent across all those products and all the clinical data that is behind them, is that some patients continue to progress.
If you look at the data from each trial, there is a residual risk, and that residual risk is shown by the fact that the risk of developing a kidney-related event or a cardiovascular event is still greater than the benefit that you see with the drug. So that speaks to the residual risk. Where we think we really fit in is knowing that some of these patients continue to progress and will end up on dialysis at some point in time. We are really there, we are positioning our therapy for those patients who are on standard of care and continue to progress. And that market is going to be a sub-fraction of the 1 million, but we still believe it is going to be a substantial market.
As a one to two-time cell therapy, it is not a chronic therapy, to be clear.
That's correct, Andrew, and so very good point there. All the other agents I mentioned, patients have to wake up every day and take those medications. If you're a diabetic with chronic kidney disease and your GFR is around 30, then you often have multiple comorbidities. You're often on a lipid-lowering agent, maybe multiple antihypertensives, maybe something to control edema, vitamin D, maybe an oral iron drug. I could go on. The average might be eight to 10 to 12 drugs on a daily basis. With rilparencel, you get two injections. You get one injection after the product is made, and three months later, you get an injection in the other kidney. First is in the biopsied kidney, and the other injection's in the contralateral kidney.
Mm-hmm. Understood. What's the latest on your payer work? Because when I think cell therapy, you could price it very high. This is also a million patient population. What does it take to get a billion in peak sales in terms of price?
Yeah, I'm going to ask James to have a go at that answer. James, if you don't mind.
Sure. Yeah, so I think when we think about pricing, we can think about it from a couple of different perspectives. First is the value, the potential value that rilparencel could bring to the U.S. healthcare system. Dialysis costs the U.S. healthcare system for patients that are covered by Medicare $100,000 annually. For patients that are covered by private payers, it can cost two or more times that amount. So one way to think about it is for every year rilparencel is able to stabilize kidney function and keep patients off of dialysis, that could deliver $200,000 of value or savings to the U.S. healthcare system. A couple of other ways to think about it is just by recent comps. Other recently launched cell therapies have launched in the $400,000-$500,000 range.
And also other recently launched treatments for other kidney diseases, IgAN as an example, have also launched in the $400,000-$500,000 range. That is an annual cost, so that would likely be a lifetime annual cost going forward. If you look at those, both the figures I gave you, which is potential savings to the U.S. healthcare system as well as comps, you can start to narrow in on what pricing might look like.
Thanks. And- Andrew, if I could, if you do not mind- Yeah Just to, James, to add on something like that, just given the fact that we are in the U.K.
I will say that dialysis costs a lot of money wherever you look across the world. There are some countries, like the U.S., that is definitely in the top tier of what is paid for dialysis, but there are other countries, some countries in Europe, that actually pay more than what the U.S. pays for dialysis, and there are a lot of countries that pay less as well. I will also say that, just to put the patient forward here too, dialysis has a huge impact on patients. Many patients go to dialysis three times per week. Most end up stopping to work because they cannot go to dialysis and continue to work. Many of them have out-of-pocket costs.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
4 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
